Traditional Chinese medicine Huanglian in the treatment of diabetes mellitus: a registration study

Internal medicine of traditional Chinese medicine (endocrine)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2200006187

Enrollment

Unknown

Registered

2022-06-21

Start date

2022-06-07

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Coptidis Rhizoma group:traditional Chinese medicine prescriptions containing Coptidis Rhizoma

non-exposed group:traditional Chinese medicine prescriptions containing Coptidis Rhizoma,the daily dosage of Coptidis Rhizoma<5g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The age is 18 to 70 years old (including boundary value), and there is no limit on gender; 2)Meet the diagnostic criteria of diabetes in modern medicine; 3)lt is planned to start taking traditional Chinese medicine prescriptions containing Coptidis Rhizoma to treat the disease; 4) Informed consent has been signed.

Exclusion criteria

Exclusion criteria: 1) Those who currently have more serious underlying diseases; 2) Patients who are taking other drugs that have significant effects on gastrointestinal function as judged by the doctor at the same time; 3) Those who are allergic to the known ingredients of the research drug and have allergic constitution; 4) The patient is complicated with other serious diseases or mental disorders; 5) Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Twelve lead ECG;Common Gastrointestinal Side Effects Scale;kidney function;Glu;liver function;HbAlc;	—

Countries

China

Contacts

Public ContactLinhua Zhao

melonzhao@163.com010-88001166

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026